Alzheimer’s Disease/Dementia News

The FDA has granted 510(k) clearance to a Centiloid scaling apparatus software for positron emission tomography-based amyloid imaging to evaluate individuals for Alzheimer’s disease-related pathology.

Increasing depressive symptoms among cognitively unimpaired older adults appeared significantly associated with early amyloid accumulation in brain regions involved in emotional control, according to a study published in JAMA Network Open.

CHICAGO — Exposure to trauma was tied to increased measures of inflammation and neuronal death for Black women and accelerated brain age indicators regardless of race and ethnicity, researchers reported.

Type 2 diabetes has emerged as a possible risk factor contributing to the development of dementia, but one class of agents used to treat the disease may provide greater protective effects, study results published in BMJ showed.

In the third episode of the NSAIDs saga, we focus on COX-2 inhibition! Did the hopes and dreams of selective COX-2 inhibition pan out? What can the rise and fall of VIOXX teach us about physiology?

PHILADELPHIA — The creation of microstimulation models may help predict population-level dementia burdens by the year 2050; however, the success of the model is dependent on the size and quality of the data, according to a presenter.

SGLT2 inhibitors and dulaglutide confer a similar risk for dementia among adults aged 60 years and older with type 2 diabetes, according to findings published in Annals of Internal Medicine.

Individuals who engaged in some form of exercise or physical activity on a regular or semi-regular basis demonstrated better brain health compared with inactive individuals, according to research from Nature Aging.

Mortality data from 1999 to 2020 revealed an upward trend in dementia-related mortality in the United States, especially among Black adults and women, according to a study published in The Primary Care Companion for CNS Disorders.